STATUTORY RULES
1970 No.
________
REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1969.*
WHEREAS it is provided by sub-section (4.) of section 101 of the National Health Act 1953-1969 that a drug or medicinal preparation that was not a pharmaceutical benefit under the National Health Act 1953-1958 immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:
AND WHEREAS that Committee has recommended to the Minister that the following additional drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953-1969, namely, the drugs and medicinal preparations inserted in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations by regulation 4 and the Third Schedule to these Regulations:
NOW THEREFORE I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1969.
Dated this twentieth day of March, 1970.
Paul Hasluck
Governor-General.
By His Excellency’s Command,
(Sgd.) A. J. Forbes.
Minister of State for Health.
_________
Amendments of the National Health (Pharmaceutical Benefits) Regulations†
Commencement.
1. These Regulations shall come into operation on the first day of April, 1970.
First Schedule.
2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.
Second Schedule.
3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.
Third Schedule.
4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Third Schedule to these Regulations.
Fourth Schedule.
5. The Fourth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—
(a) by adding at the end of item 15 the letters “ , B.P.C.”;
(b) by omitting items 18 and 19; and
(c) by adding at the end of item 22 the letters “ , B.P.”.
_________________________________________________________________________
* Notified in the Commonwealth Gazette on 1970.
† Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos. 51, 151 and 152; 1966, Nos. 80 and 144; 1967, Nos. 67, 116 and 158; 1968, Nos. 44, 76, 88 and 146; and 1969, Nos. 44, 107 and 185.
12752/70—Price 25c 10/13.3.1970
Fifth Schedule.
6. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the following Schedule is inserted in its stead:—
FIFTH SCHEDULE Regulation 14.
Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
1 | Acetylcholine Chloride with Mannitol, B.P. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
2 | Acetylcysteine ................. | Cystic Fibrosis (mucoviscidosis) |
3 | (1) Aspirin Tablets, B.P. ........... | Any disease or condition in a pensioner |
| (2) Soluble Aspirin Tablets, B.P. |
|
| (3) Aspirin with Paracetamol and Caffeine Tablets |
|
| (4) Aspirin with Codeine Phosphate and Pentobarbitone Sodium Tablets |
|
4 | Acrylic Resin ................. | Ileostomy or colostomy conditions |
5 | Albumaid XP ................. | With the written authority of the Director-General, Phenylketonuria |
6 | Aldosterone .................. | With the written authority of the Director-General, treatment of an acute crisis in— |
|
| Adrenal cortical hypofunction (including Addison’s disease and salt-losing congenital adrenal hypoplasia) |
7 | Allopurinol ................... | Crystalluria due to uric acid |
|
| Gout associated with renal failure or nephrolithiasis |
|
| Chronic gout not responding to other agents |
|
| Ankylosing spondylitis |
8 | Aloxiprin .................... | Osteoarthritis |
|
| Psoriatic arthropathy |
|
| Rheumatoid arthritis |
9 | Alprenolol Injection ............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
10 | Alprenolol Tablet ............... | With the written authority of the Director-General, Idiopathic hypertrophic subaortic stenosis |
|
| Ankylosing spondilitis |
11 | Aluminium Acetylsalicylate Tablet | Osteoarthritis |
|
| Psoriatic arthropathy |
|
| Rheumatoid arthritis |
12 | Ambenonium Chloride ........... | Myasthenia gravis |
13 | Aminocaproic Acid ............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
14 | Aminosalicylic Acid ............. | Tuberculosis |
15 | (1) Amitriptyline Hydrochloride ..... | Any disease or condition in a pensioner |
| (2) Amitriptyline Tablets, B.P. | The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Amitriptyline Hydrochloride or Amitriptyline Tablets, B.P. |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
16 | Amphotericin B Injection ......... | Systemic mycoses |
17 | (1) Amphotericin B Tablets ........ | Moniliasis |
| (2) Amphotericin B Lozenge |
|
| (3) Amphotericin B Suspension |
|
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
18 | (1) Ampicillin Capsules, B.P........ | Infections of the ear or respiratory tract where they cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin |
| (2) Ampicillin Injections, Tablets and Suspension | |
|
| Gram-negative infections where ampicillin appears to be the most suitable drug |
|
| Any bacterial infection of the genito-urinary tract which cannot be safely or effectively treated with sulphonamides |
|
| Broad spectrum antibiotic treatment of patients undergoing steroid therapy or recently subjected to steroid therapy |
|
| Pancreatitis, meningitis, any infection in pregnant women or in children where these cannot be safely and effectively treated with sulphonamides, phenoxymethyl-penicillin or phenethicillin |
19 | Angiotensin Amide ............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
20 | Ascorbic Acid Tablets, B.P......... | Any disease or condition in a pensioner |
21 | Azathioprine .................. | With the written authority of the Director-General, azathioprine therapy for a person who has been discharged from an approved hospital and received that therapy while a patient in the hospital |
22 | Beclamide ................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
23 | Benzathine Penicillin, B.P.......... | Prophylaxis of recurrent streptococcal infections, (including rheumatic fever) |
24 | Benzoin Compound Tincture, B.P.C. aerosol spray | Ileostomy or colostomy conditions |
25 | Benzylpenicillin Injection, 5,000,000 units | Bacterial endocarditis or septicaemia |
26 | (1) Benzylpenicillin Tablets, B.P. | Prophylaxis of recurrent streptococcal infections, (including rheumatic fever) |
| (2) Benzylpenicillin Capsules | |
27 | Benzylpenicillin Injection, 10,000,000 units | Bacterial endocarditis or septicaemia |
| Gastrointestinal surgery | |
28 | (1) Benzylpenicillin with Streptomycin Sulphate | Endocarditis due to Streptococcus faccalis or Streptococcus viridans |
| (2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate |
|
29 | Betahistine Hydrochloride ......... | Meniere’s Syndrome |
30 | (1) Betamethasone Acetate and Betamethasone Injection | Intra-articular use |
| With the written authority of the Director-General, | |
| (2) Betamethasone Sodium Phosphate Injection, B.P. | Pre-operative and post-operative prophylactic therapy for those patients undergoing or recently subjected to steroid therapy |
31 | Betamethasone Valerate with Clioquinol | For the treatment of diseases of the ear |
32 | Buclosamide with Salicylic Acid .... | For the treatment of diseases of the ear |
33 | Buclosamide, Salicylic Acid and Hydrocortisone Acetate | For the treatment of diseases of the car |
34 | Busulphan Tablets, B.P............ | Treatment in malignant neoplasia |
35 | (1) Calciferol Tablets, Strong, B.P..... | Any disease or condition in a pensioner |
| (2) Calciferol, B.P............... | With the written authority of the Director-General— |
|
| Hypoparathyroidism |
|
| Osteomalacia following gastrectomy |
|
| Vitamin D-resistant rickets |
36 | Calcium Aminosalicylate ......... | Tuberculosis |
37 | Capreomycin Sulphate ........... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
38 | Carbamazepine ................ | Epilepsy |
|
| Trigeminal neuralgia |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
39 | Carbenicillin ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
40 | (1) Carbenoxolone Sodium ........ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Cephaloridine .............. | |
41 | Charcoal Tablets ............... | Ileostomy or colostomy conditions |
42 | Chlorambucil Tablets, B.P......... | Treatment in malignant neoplasia |
43 | Chloramine Deodorant Tablets and Powder | Ileostomy or colostomy conditions |
44 | (1) Chloramphenicol Capsules, B.P. | Bacterial meningitis |
| (2) Chloramphenicol Injections | Intraocular infectious |
| (3) Chloramphenicol Oral Suspension | Rickettsioses |
| Typhoid | |
|
| The treatment of other serious infections in a patient where it is established by appropriate bacteriological testing that Chloramphenicol is the only suitable antibiotic listed as a pharmaceutical benefit, for use in treating the infection in the patient |
45 | Chlorotrianisene Tablets .......... | Carcinoma of the prostate |
46 | (1) Chlorpromazine Hydrochloride, B.P. | Any disease or condition in a pensioner |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, B.P., Chlorpromazine Injection, B.P., or Chlorpromazine Tablets, B.P. | |
| (2) Chlorpromazine Injection, B.P. | |
| (3) Chlorpromazine Tablets, B.P. | |
|
| With the written authority of the Director-General— |
|
| Hereditary chorea (Huntington’s) |
|
| Malignant neoplasia (late stage) |
|
| Radiation sickness |
|
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
47 | Clofibrate ................... | With the written authority of the Director-General— |
|
| Diabetic retinopathy (exudative) |
|
| Hypercholesterolaemia with xanthomata |
|
| Hypercholesterolaemia, familial (essential) |
48 | (1) Cloxacillin Sodium, B.P........ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Cloxacillin Capsules, B.P. | |
49 | (1) Codeine Phosphate with Aspirin Soluble Tablets | Any disease or condition in a pensioner |
| (2) Codeine Phosphate with Aspirin Tablets |
|
| (3) Codeine Phosphate with Aspirin and Paracetamol Soluble Tablets |
|
| (4) Codeine Phosphate with Aspirin and Paracetamol Tablets |
|
| (5) Codeine Phosphate with Aspirin, Paracetamol and Caffeine Tablets |
|
50 | Cod Liver Oil Emulsion .......... | Any disease or condition in a child under the age of twelve years or in a pensioner |
51 | Colistin Sulphomethate Sodium, B.P., for injection | Pyocyaneus infection, other Gram-negative infections where no other drug is effective |
52 | (1) Corticotrophin Injection, B.P. | With the written authority of the Director-General— |
| (2) Corticotrophin Gelatin Injection, B.P. | The prevention of side effects of corticosteroid therapy |
| (3) Corticotrophin Zinc Hydroxide Injection, B.P. |
|
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whoso treatment it may be prescribed) for supply under Part VII. of the Act |
52— | (1) Corticotrophin Injection, B.P. | Acquired haemolytic anaemia |
contd | (2) Corticotrophin Gelatin Injection, B.P. | Acute disseminated encephalomyelitis |
| Acute exacerbations of multiple sclerosis | |
| (3) Corticotrophin Zinc Hydroxide Injection, B.P. | Acute exacerbations of multiple sclerosis |
| Acute exfoliative dermatitis | |
|
| Acute phase of Bell’s Palsy |
|
| Acute rheumatic carditis |
|
| Addison’s disease or other forms of adrenocortical hypoplasia |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet’s syndrome |
|
| Cranial arteritis |
|
| Cushing’s syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen’s disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin’s disease |
|
| Hypoplastic anaemia |
|
| Hypsarrhythmia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch’s |
|
| Regional ileitis (Crohn’s disease) |
|
| Reticulum cell sarcoma |
|
| Salaam convulsions |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still’s disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
52— |
| Temporal arteritis |
contd |
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with those diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
53 | Cortisone Injection, B.P........... | With the written authority of the Director-General— |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Anaemia, acquired haemolytic |
|
| Addison’s disease |
|
| Adrenocortical hypoplasia |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Angioneurotic oedema |
|
| Behcet’s syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral tumours and cerebral oedema |
|
| Cranial arteritis |
|
| Cushing’s syndrome, including hyperadrenocorticalism |
|
| Dermatitis, acute exfoliative |
|
| Dermatitis herpetiformis |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Encephalomyelitis, acute disseminated |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen’s disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin’s disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Oedema of the spinal cord following trauma or infection |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch’s |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
53—contd | Cortisone Injection, B.P........... | Purpura, thrombocytopenic |
| Regional ileitis (Crohn’s disease) | |
|
| Reticulum cell sarcoma |
|
| Retroperitoneal fibrosis |
|
| Rheumatic carditis, acute |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation in patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still’s disease in a child under the age of sixteen years |
|
| Sneddon and Wilkinson’s sub-corneal pustular dermatosis |
|
| Sympathetic ophthalmitis |
|
| Systemic lupus erythematosus |
|
| Temporal arteritis |
|
| Total adrenalectomy |
|
| Treatment of malignancy in conjunction with radiotherapy or chemotherapy |
|
| Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
54 | Cyanocobalamin Injection, B.P...... | Pernicious anaemia and other proven Vitamin B-12 deficiencies |
|
| Post gastrectomy treatment |
|
| Sub-acute combined degeneration of the cord |
|
| Neuroblastoma |
55 | (1) Cycloserine Tablets, B.P........ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Cycloserine Capsules, B.P. | |
58 | Cymogran ................... | With the written authority of the Director-General, phenylketonuria |
|
| |
57 | (1) Cyproheptadine Hydrochloride, B.P. | Allergic rhinitis |
| (2) Cyproheptadine Tablets, B.P. | Allergic dermatoses |
58 | Cytosine Arabinoside Hydrochloride | Any disease or condition in a patient receiving treatment in or at an approved hospital |
59 | (1) Deodorant Detergent Solution (Terric N.8 with Spearmint Oil and Cetrimide) | Ileostomy or colostomy conditions |
| (2) Deodorant Detergent Solution (Lauryldimethyl Benzyl Ammonium Chloride and Terric N.8) |
|
60 | (1) Deoxycortone Aqueous Injections | Adrenal cortical hypofunction including Addison’s disease |
| (2) Deoxycortone Acetate Injection, B.P. | Total adrenalectomy |
| (3) Deoxycortone Trimethylacetate Injection, B.P. |
|
| (4) Deoxycortone Acetate Implants, B.P. |
|
| (5) Deoxycortone Acetate Tablets |
|
61 | Desferrioxamine ............... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
62 | Dexamethasone Sodium Phosphate Injections | Intra-articular use |
| Cerebral oedema | |
63 | (1) Dextromoramide Tablets, B.P. | Treatment in malignant neoplasia |
| (2) Dextromoramide Tartrate, B.P. |
|
64 | Diazepam Injection ............. | Electrical conversion of cardiac arrythmias (cardioversion) |
|
| Endoscopy |
|
| Epilepsy |
|
| Minor operative procedures |
|
| Upper motor neurone lesion |
|
| Premedication induction of anaesthesia |
65 | Diazepam Syrup and 10 mg. Tablet | Epilepsy |
|
| Upper motor neurone lesion |
66 | Diazepam Tablets 2 mg. and 5 mg | Epilepsy |
|
| Upper motor neurone lesion |
|
| Multiple sclerosis |
|
| Stiff-man syndrome |
67 | Dicyclomine Hydrochloride with Doxylamine Succinate and Pyridoxine Hydrochloride | Vomiting in pregnancy |
68 | Dienoestrol Cream .............. | Any disease or condition in a pensioner |
69 | Diethanolamine Fusidate, B.P.C. | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Diethanolamine Fusidate is the only appropriate antibiotic that is listed as a benefit |
70 | Dihydroergotoxine Mesylate ....... | For the treatment of patients who have suffered an attack of paralytic poliomyelitis |
| (1) Tablets | |
| (2) Injections |
|
71 | Dihydrotachysterol .............. | Hypoparathyroidism |
72 | Diloxanide Furoate Tablets, B.P...... | Intestinal amoebiasis |
73 | Dimethicone Aerosol Spray........ | Ileostomy or colostomy conditions |
74 | Dimethicone Creams ............ | Use with surgical appliances |
75 | Dioetyl Sodium Sulphosuccinate with Danthron | Any disease or condition in a pensioner |
76 | Disodium Cromoglycate .......... | With the written authority of the Director-General— |
|
| The prevention of asthma for a patient who is under 18 years of age, whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and whose re-occurrences of asthma could not be controlled by adequate use of bronchodilaters and other standard means of prevention and treatment |
|
| The prevention of asthma for a patient whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and to require the continuous use of over 7.5 mg. of prednisone, or its equivalent, daily or who suffers from a disease indicating that corticosteroid therapy should not be applied, such as peptic ulcer, hypertension of 180/100 or more before treatment, diabetes, osteoporosis proven by X-ray or steroid induced myopathy |
77 | Disodium Stilboestrol Diphosphate | Carcinoma of the prostate |
78 | Ditophal ..................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
79 | Droperidol ................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
80 | (1) Erythromycin Estolate Capsules B.P. | Amoebiasis |
Brucellosis | ||
| (2) Erythromycin Estolate, B.P. | Leptospirosis |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
80—contd | (3) Erythromycin Tablets, B.P. | Lymphogranuloma venereum |
(4) Erythromycin Ethyl Succinate | Pneumonia due to mycoplasma pneumoniae | |
| (5) Erythromycin Glucoheptonate | Psittacosis |
| (6) Erythromycin Lactobionate | Rickettsioses |
| (7) Erythromycin Stearate, B.P. | Staphylococcal septicaemia or staphylococcal pneumonia |
| (8) Erythromycin Stearate Tablets, B.P. | Actinomycosis, Trachoma, or any bacterial or spirochaetal infections where these cannot be safely and effectively treated with sulphonamides, phenoxymethylpenicillin or phenethicillin |
81 | Ethacrynic Acid ............... | Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome |
|
| Fluid retention associated with other conditions and not responding to thiazides |
82 | Ethinyloestradiol Tablets, B.P....... | Any disease or condition in a pensioner |
|
| Carcinoma of the prostate |
|
| Hereditary telangiectasis |
|
| Menopause, premature; surgically induced |
|
| Turner’s syndrome |
83 | Ethionamide .................. | Tuberculosis |
84 | Ethisterone Tablets, B.P........... | Turner’s syndrome |
85 | Ethyloestrenol ................ | With the written authority of the Director-General— |
|
| Intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long term treatment with corticosteroids |
|
| Osteomalacia following gastrectomy |
86 | Fludrocortisone Tablets, B.P........ | Adrenal cortical hypoplasia including Addison’s disease |
|
| Total adrenalectomy |
87 | Flufenamic Acid ............... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
88 | Flumethasone Pivalate and Clioquinol | For the treatment of diseases of the ear |
89 | Fluorouracil Sodium ............ | Treatment in malignant neoplasia |
90 | Fluoxymesterone Tablets, B.P ...... | Eunuchism |
|
| Carcinoma of the breast |
|
| With the written authority of the Director-General— |
|
| Intermittent use for corticosteroid-induced osteoporosis |
|
| Proven aplastic anemias |
91 | Fluphenazine Enanthate .......... | The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits— |
|
| Fluphenazine Enanthate |
|
| Fluphenazine Hydrochloride |
|
| With the written authority of the Director-General— |
|
| Hereditary chorea (Huntington’s) |
|
| Malignant neoplasia (late stage) |
|
| Radiation sickness |
|
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
92 | Fluphenazine Hydrochloride ....... | Any disease or condition in a pensioner |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
92—contd |
| discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits— |
|
| Fluphenazine Enanthate |
|
| Fluphenazine Hydrochloride |
|
| With the written authority of the Director-General— |
|
| Hereditary chorea (Huntington’s) |
|
| Malignant neoplasia (late stage) |
|
| Radiation sickness |
|
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
93 | (1) Folic Acid, B.P.............. | Proven folic acid deficiency |
| (2) Folic Acid Tablets, B.P. 5 mg. | Sprue or the sprue-like syndrome |
94 | Folic Acid Tablets, B.P. 1 mg....... | Pregnancy |
95 | Folinic Acid ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
96 | Framycetin Sulphate Tablets ....... | Bowel sterilization preparatory to major surgery |
97 | Frusemide Tablets, B.P........... | Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome |
|
| Fluid retention associated with other conditions and not responding to thiazides |
98 | Galactomin Formula No. 17 ....... | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Conditions needing an extreme restriction of lactose in the patient’s diet, under the age of four years |
99 | Galactomin Formula No. 19 ....... | With the written authority of the Director-General, Glucose-galactose malabsorption |
100 | Gentamicin Sulphate ............ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
101 | Glucose Indicator—Blood ........ | With the written authority of the Director-General, Diabetes mellitus in which adequate control is impossible by any other means because of low renal threshold |
102 | Goat’s Milk, Dehydrated ......... | With the written authority of the Director-General, cow’s milk allergy in children under the age of four years |
103 | Goat’s Milk, Whole (Sterilised) ..... | With the written authority of the Director-General, cow’s milk allergy in children under the age of four years |
104 | Griseofulvin Tablets, B.P.......... | With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination or Wood’s Light |
105 | Guanacline Tablets ............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
106 | Halibut Liver Oil Capsules ........ | Any disease or condition in a pensioner |
107 | Haloperidol .................. | Any disease or condition in a pensioner |
|
| The treatment of a mental disorder in a person who has after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Haloperidol |
|
| With the written authority of the Director-General— |
|
| Hereditary chorea (Huntington’s) |
|
| Malignant neoplasia (late stage) |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
107— |
|
Radiation sickness |
contd |
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
108 | (1) Hexachlorophane with Chloroxylenol | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| (2) Hexachlorophane with Entsufon |
|
| (3) Hexachlorophane with Lissapol |
|
| (4) Hexachlorophane in Soap Solution |
|
109 | Hydrocortisone Injection ......... | With the written authority of the Director-General— |
|
| Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exfoliative dermatitis |
|
| Acute exophthalmic ophthalmoplegia |
|
| Acute heart block complicating myocardial infarction |
|
| Acute rheumatic carditis |
|
| Addison’s disease or other forms of adrenocortical hypoplasia |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Angioneurotic oedema |
|
| Behcet’s syndrome |
|
| Benign intracranial hypertension |
|
| Cerebral oedema |
|
| Cerebral tumors |
|
| Cranial arteritis |
|
| Cushing’s syndrome including hyperadrenocorticalism |
|
| Dermatitis herpetiformis |
|
| Dermatomyositis |
|
| Encephalitis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome diffuse interstitial pulmonary fibrosis |
|
| Hansen’s disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin’s disease |
|
| Hypoplastic anaemia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Interstitial keratitis due to syphilis or vernal conjunctivitis |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
|
| Lymphosarcoma and follicular lymphoma |
|
| Malignancy treatment in conjunction with radiotherapy or chemotherapy |
|
| Meningitis |
|
| Metastatic breast cancer |
|
| Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
109—contd |
Hydrocortisone injection .......... |
Neuromyelitis optica |
|
| Oedema of the spinal cord following trauma or infections |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch’s |
|
| Regional ileitis (Crohn’s disease) |
|
| Reticulum cell sarcoma |
|
| Retroperitoneal fibrosis |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Sneddon and Wilkinson’s sub-corneal pustular dermatosis |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steriod therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still’s disease in children under the age of sixteen years |
|
| Sympathetic ophthalmitis |
|
| Systemic lupus erythematosus |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Total adrenalectomy |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with these diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
110 | Hydrocortisone Acetate Injection, B.P. | Intra-articular use |
111 | Hydrocortisone Acetate, B.P. with Neomycin Sulphate, B.P. Ear drops and ear ointment | For the treatment of diseases of the ear |
112 | Hydrocortisone with 1,2-Propanediol Diacetate and Acetic Acid | For the treatment of diseases of the ear |
113 | Hydrocortisone Sodium Succinate Injection | Acute adrenal cortical hypofunction due to medical or surgical crisis |
|
| Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subjected to steroid therapy |
|
| Stevens-Johnson disease |
114 | Hydrocortisone Ear Drops ......... | For the treatment of diseases of the ear |
115 | Hydroxocobalamin Injection, B.P. | Pernicious anaemia and other proven Vitamin B-12 deficiencies |
|
| Post gastrectomy treatment |
|
| Sub-acute combined degeneration of the cord |
|
| Neuroblastoma |
116 | Hydroxyprogesterone Caproate ..... | Carcinoma of the endometrium |
|
| Progesterone deficiency proved by hormonal assay, by lateral wall smear or by endometrial biopsy |
117 | Idoxuridine .................. | Infectious caused by Herpes Simplex Virus |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
118 | (1) Imipramine Tablets, B.P........ | Any disease or condition in a pensioner |
| (2) Imipramine Hydrochloride, B.P. | The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Imipramine Hydrochloride, B.P. or Imipramine Tablets, B.P. |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
119 | Indomethacin Capsules .......... | Acute gout |
|
| Ankylosing spondylitis |
|
| Leontiasis osseum |
|
| Osteoarthritis not responding to salicylates |
|
| Psoriatic arthropathy |
|
| Reiter’s syndrome |
|
| Rheumatoid arthritis not responding to salicylates |
120 | Indomethacin Suppositories ....... | For the treatment of the following conditions in persons who cannot tolerate oral indomethacin— |
|
| Acute gout |
|
| Ankylosing spondylitis |
|
| Leontiasis osseum |
|
| Osteoarthritis not responding to salicylates |
|
| Psoriatic arthropathy |
|
| Reiter’s syndrome |
|
| Rheumatoid arthritis not responding to salicylates |
121 | Influenza Vaccine .............. | For prophylaxis of pensioners only |
122 | Insect Allergen Extract—Honey Bee | For the treatment of severe constitutional reaction to bee stings |
123 | Isoniazid Tablets, B.P............ | Tuberculosis |
124 | Isoprenaline Hydrochloride Tablets, 30 mg. | Stokes-Adams syndrome |
125 | Kanamycin Sulphate Capsules, Injections and Oral Solution | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the most appropriate antibiotic |
126 | Kitasamycin ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
127 | Levorphanol Tartrate ............ | Obstetrical use |
|
| Severe intractable pain |
128 | Lignocaine Injection, B.P.......... | Cardiac arrhythmias |
129 | Lincomycin Hydrochloride........ | Gram positive coccal infections where these cannot be safely and effectively treated with penicillin and where resistance to erythromycin has been established by laboratory investigation |
|
| Osteomyelitis |
130 | Liothyronine Tablets, B.P.......... | Myxoedema |
131 | Lofenalac ................... | With the written authority of the Director-General, phenylketonuria |
132 | Lypressin Nasal Spray ........... | Diabetes insipidus |
133 | Maphenide Acetate ............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
134 | Medroxyprogesterone Acetate Tablets, 2.5 mg. | Carcinoma of the endometrium |
135 | Medroxyprogesterone Acetate Tablets, 10 mg. | Carcinoma of the endometrium |
Precocious puberty | ||
136 | Medroxyprogesterone Acetate Tablets, 100 mg. | Carcinoma of the breast |
Carcinoma of the endometrium | ||
|
| Hypernephroma |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
137 | Medroxyprogesterone Acetate Injections | Carcinoma of the endometrium |
Hypernephroma | ||
|
| Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy |
138 | Melphalan ................... | Treatment in malignant neoplasia |
139 | Mercaptopurine Tablets, B.P........ | Allergic granulomatous angiitis |
|
| Lupus erythematosus |
|
| Nephrotic syndrome |
|
| Periarteritis (Nodosa) |
|
| Treatment in malignant neoplasia |
140 | (1) Methandienone Tablets, B.P. | With the written authority of the Director-General— |
| (2) Methenolone Acetate | Intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
141 | Methicillin Sodium, B.P. for Injection | Proven or suspected staphylococcal septicaemia |
142 | Methotrexate Tablets ............ | Treatment in malignant neoplasia |
143 | Methotrexate Injections .......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
144 | Methylprednisolone Acetate Injection | Intra-articular use |
145 | (1) Methyltestosterone Tablets, B.P. | Carcinoma of the breast |
| Eunuchism | |
| (2) Methyltestosterone, B.P. | Klinefelter’s syndrome (seminiferous tubule dysgenesis) |
146 | Methysergide Maleate ........... | With the written authority of the Director-General, migraine, severe recalcitrant when other treatment has failed |
147 | Metyrapone .................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
148 | Minafen .................... | With the written authority of the Director-General, phenylketonuria |
149 | Morphine Sulphate, B.P. with Tacrine Tablets | Severe intractable pain |
150 | Mustine Hydrochloride Injection | Treatment in malignant neoplasia |
151 | Nalidixic Acid ................ | Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective |
152 | Nandrolone Decanoate ........... | Carcinoma of the breast |
|
| With the written authority of the Director-General— |
|
| Intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
|
| Severe osteoporosis due to proven pancreatitis |
153 | Nandrolone Hexoxyphenyl Propionate | Carcinoma of the breast |
| With the written authority of the Director-General— | |
|
| Intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
154 | Nandrolone Phenylpropionate Injection, B.P. | Carcinoma of the breast |
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis | ||
155 | (1) Natamycin Oral Tablets ....... | Moniliasis |
| (2) Natamycin Oral Suspension |
|
156 | Neomycin Sulphate Powder ....... | With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis) |
157 | Neomycin Sulphate, B.P. with Gramicidin, Thonzonium Bromide, Thonzylamine Hydrochloride and Hydrocortisone | For the treatment of diseases of the ear |
| Acetate, B.P. |
|
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
158 | Neomycin Tablets, B.P........... | Bowel sterilization preparatory to major surgery |
|
| Encephalopathy, hepatic |
159 | Neomycin Undecenoate with Bacitracin Zinc | For the treatment of diseases of the ear |
160 | Nicotinic Acid Tablets, B.P........ | Any disease or condition in a pensioner |
161 | Nitrazepam .................. | Myoclonic epilepsy |
162 | (1) Nitrofurantoin Tablets, B.P...... | Urinary tract infections where positive bacteriological evidence shows sulphonamides to be ineffective |
| (2) Nitrofurantoin Oral Suspension | |
163 | Nitromin .................... | Treatment in malignant neoplasia |
164 | Norethisterone Acetate, B.P........ | Carcinoma of the breast |
165 | (1) Nortriptyline Hydrochloride, B.P. | Any disease or condition in a pensioner |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Nortriptyline Hydrochloride, B.P., Nortriptyline Tablets, B.P. or Nortriptyline Capsules, B.P. | |
| (2) Nortriptyline Tablets, B.P. | |
| (3) Nortriptyline Capsules, B.P. | |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
166 | Nutramigen .................. | With the written authority of the Director-General— |
|
| Cow’s milk allergy in children under the age of four years |
|
| Cystic Fibrosis (mucoviscidosis) |
|
| Galactosaemia |
|
| Lactose intolerance |
167 | Nystatin Tablets, B.P............. | Moniliasis |
168 | Orciprenaline Sulphate Injection | Any disease or condition in a patient receiving treatment in or at an approved hospital |
169 | Oxprenolol Tablet .............. | With the written authority of the Director-General, idiopathic hypertrophic subaortic stenosis |
170 | Oxprenolol Injection ............ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
171 | Oxycodone Pectinate ............ | Treatment in malignant neoplasia |
172 | Oxymetholone ................ | With the written authority of the Director-General, Proven aplastic or hypoplastic anaemias (familial) |
173 | (1) Pancreatin, B.P.............. | Cystic Fibrosis (mucoviscidosis) |
| (2) Pancreatin Enzyme 4 X | Following pancreatico—duodenectomy |
| U.S.N.F. XII | Pancreatic steatorrhoea |
| (3) Pancrelipase |
|
174 | (1) Paracetamol Suspension ....... | Any disease or condition in a pensioner |
| (2) Paracetamol Tablets, B.P. |
|
175 | Paracetamol with Codeine Phosphate and Pentobarbitone Sodium | Any disease or condition in a pensioner |
176 | (1) Paraffin Liquid Emulsion ...... | Any disease or condition in a pensioner |
| (2) Paraffin Liquid Emulsion with Phenolphthalein |
|
177 | Pargyline Hydrochloride ......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
178 | Penicillamine ................. | With the written authority of the Director-General— |
|
| Acute heavy metal intoxication |
|
| Cystinosis |
|
| Cystinuria with calculus formation |
|
| Haemoglobinuria, paroxysmal cold |
|
| Wilson’s disease (hepatolenticular degeneration) |
179 | Pethidine Hydrochloride with Levallorphan Tartrate | Obstetric use |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
180 | (1.) Phenylbutazone Tablets, B.P. | Acute Gout |
| (2) Phenylbutazone Capsules | Ankylosing spondylitis |
|
| Osteoarthritis not responding to salicylates |
|
| Psoriatic arthropathy |
|
| Reiter’s syndrome |
|
| Rheumatoid arthritis not responding to salicylates |
181 | (1) Phenylbutazone Suppositories | For the treatment of the following conditions in persons who cannot tolerate oral Phenylbutazone— |
| (2) Phenylbutazone Injection | |
|
| Acute gout |
|
| Ankylosing spondylitis |
|
| Osteoarthritis not responding to salicylates |
|
| Psoriatic arthropathy |
|
| Reiter’s syndrome |
|
| Rheumatoid arthritis not responding to salicylates |
182 | Phytomenadione Injection, B.P..... | Antidote to anticoagulants |
183 | Phytomenadione Injection, B.P. ..1 mg. | Antidote to anticoagulants |
| Suspected cerebral trauma of the new born | |
|
| Haemorrhagic disease of the new born |
184 | Pituitary, Posterior Lobe, Insufflation | Diabetes insipidus |
185 | Plasma Substitute (Polypeptide).... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
186 | Polymyxin B. Sulphate Powder.... | With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis) |
187 | Polymyxin B. Sulphate Neomycin Sulphate and Hydrocortisone | For the treatment of diseases of the ear |
188 | Polymyxin B. Sulphate with Bacitracin and Neomycin Sulphate Ear drops | For the treatment of diseases of the ear |
189 | Polymyxin B. Sulphate with Lignocaine Hydrochloride and Propylene Glycol | For the treatment of diseases of the ear |
190 | Polyoestradiol Phosphate........ | Carcinoma of the breast |
|
| Carcinoma of the prostate |
191 | Prednisolone Sodium Phosphate Retention Enema and Suppository | With the written authority of the Director-General— |
| Ulcerative colitis proven by sigmoidoscopy or radiological report | |
|
| Proctitis proven by sygmoidoscopy |
192 | (1) Prednisolone Acetate Injection | Intra-articular use |
| (2) Prednisolone Butyl Acetate Injection |
|
193 | Prednisolone Sodium Phosphate and Neomycin Sulphate | For the treatment of diseases of the ear |
194 | Prednisolone Sodium Succinate Injection | Acute adrenal cortical hypofunction due to any medical or surgical crises |
|
| Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subjected to steroid therapy |
|
| Stevens-Johnson disease |
195 | Procarbazine Hydrochloride....... | Treatment in malignant neoplasia |
196 | (1) Prochlorperazine............ | Meniere’s Syndrome |
| (2) Prochlorperazine Tablets, B.P... |
|
197 | Progesterone................. | Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy |
|
| |
198 | Propranolol Injection, B.P........ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
199 | Propranolol Tablets, B.P......... | With the written authority of the Director-General, idiopathic hypertrophic subaortic stenosis |
200 | Prosobee................... | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Homocystinuria |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
200—contd |
| Lactose intolerance |
| Milk allergy in children under the age of four years | |
201 | Protriplyline Hydrochloride........ | Any disease or condition in a pensioner |
|
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Protriptyline Hydrochloride |
|
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
202 | Pyrazinamide................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
203 | (1) Pyridostigmine Injection, B.P.... | Myasthenia gravis |
| (2) Pyridostigmine Tablets, B.P..... |
|
204 | Pyridoxine Hydrochloride Tablets | Homocystinuria |
|
| Radiation sickness |
|
| Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy |
205 | Pyrimethamine Tablets........... | Toxoplasmosis |
|
| Malaria |
206 | (1) Riboflavine Tablets........... | Any disease or condition in a pensioner |
| (2) Senna Fruit Extract (standardised) |
|
207 | Sobee...................... | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Homocystinuria |
|
| Lactose intolerance |
|
| Milk allergy in children under the age of four years |
208 | (1) Sodium Aminosalicylate Tablets, B.P. | Tuberculosis |
| (2) Sodium Aminosalicylate Injection |
|
| (3) Sodium Aminosalicylate Cachets |
|
| (4) Sodium Aminosalicylate Granules |
|
| (5) Sodium Aminosalicylate with Isoniazid, B.P. |
|
209 | Sodium Folate................. | Proven folic acid deficiency |
|
| Sprue or the sprue-like syndrome |
210 | Sodium Fusidate............... | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Sodium Fusidate is the only appropriate antibiotic that is listed as a benefit |
211 | Soyalac..................... | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Homocystinuria |
|
| Lactose intolerance |
|
| Milk allergy in children under the age of four years |
212 | Spiramycin................... | Staphylococcal septicaemia or staphylococcal pneumonia |
|
| Toxoplasmosis, active-serologically proven |
|
| Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins |
213 | Spironolactone Tablets, B.P........ | With the written authority of the Director-General— |
|
| To supplement other diuretics when these have |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
213—contd |
| proved inadequate |
| Myasthenia gravis | |
214 | Stanolone................... | Carcinoma of the breast |
|
| With the written authority of the Director-General— |
|
| Intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
215 | Stanozolol................... | With the written authority of the Director-General— |
|
| Intermittent use for corticosteroid-induced osteoporosis |
|
| Intermittent use for patients on long-term treatment with corticosteroids |
216 | Streptokinase................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
217 | Sulphasalazine................ | Ulcerative colitis |
218 | Sulthiame................... | For use where other anticonvulsants have failed |
219 | (1) Surgical Cement............ | Ileostomy or colostomy conditions |
| (2) Surgical Cement Solvent | For use with surgical appliances |
220 | (1) Sustanon................. | Eunuchism |
| (2) Testosterone Implants, B.P. | Klinefelter’s syndrome (seminiferous tubule dysgenesis) |
| (3) Testosterone Enanthate | |
| (4) Testosterone Propionate Injection, B.P. | Carcinoma of the breast |
221 | Tetanus Antitoxin, B.P. (Bovine) | Patients who have previously received an injection of equine serum |
222 | Tetracosactrin Injection Set 250 mg. and 2 ml. solution | Any disease or condition in a patient receiving treatment in or at an approved hospital |
223 | Tetracosactrin Injections— | With the written authority of the Director-General— |
| 1 mg. in 1 ml................. | The prevention of side effects of corticosteroid therapy |
| 2 mg. in 2 ml................. | |
|
| Acquired haemolytic anaemia |
|
| Acute disseminated encephalomyelitis |
|
| Acute exacerbations of multiple sclerosis |
|
| Acute exfoliative dermatitis |
|
| Acute phase of Bell’s Palsy |
|
| Acute rheumatic carditis |
|
| Addison’s disease or other forms of adrenocortical hypoplasia |
|
| Adrenogenital syndrome |
|
| Agranulocytosis |
|
| Behcet’s syndrome |
|
| Cranial arteritis |
|
| Cushing’s syndrome including hyperadrenocorticalism |
|
| Dermatomyositis |
|
| Encephalomyelitis |
|
| Giant cell thyroiditis proven by biopsy |
|
| Guillain-Barré syndrome |
|
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
|
| Hansen’s disease |
|
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
|
| Hodgkin’s disease |
|
| Hypoplastic anaemia |
|
| Hypsarrhythmia |
|
| Idiopathic hypercalcaemia |
|
| Inflammatory conditions of the uveal tract and retina |
|
| Keratoplasty |
|
| Leucine sensitive hypoglycaemia |
|
| Leukaemia |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
223—contd | Tetracosactrin Injections— | Lymphosarcoma and follicular lymphoma |
1 mg. in 1 ml. | Metastatic breast cancer | |
| 2 mg. in 2 ml. | Mycosis fungoides |
|
| Nephrosis or nephrotic syndrome |
|
| Neuromyelitis optica |
|
| Optic neuritis following removal of tumors of the brain |
|
| Panhypopituitarism |
|
| Pemphigus |
|
| Periarteritis |
|
| Progressive transverse myelitis |
|
| Pseudohermaphroditism |
|
| Pulmonary eosinophilia |
|
| Purpura, Henoch’s |
|
| Regional ileitis (Crohn’s disease) |
|
| Reticulum cell sarcoma |
|
| Salaam convulsions |
|
| Sarcoidosis |
|
| Scleroderma |
|
| Severe reactions of the skin and mucosa following X-ray therapy |
|
| Splenic neutropenia |
|
| Status asthmaticus |
|
| Steroid therapy prior to operation for those patients under steroid therapy |
|
| Stevens-Johnson syndrome |
|
| Still’s disease in children under the age of sixteen years |
|
| Systemic lupus erythematosus |
|
| Sympathetic ophthalmitis |
|
| Temporal arteritis |
|
| Thrombocytopenic purpura |
|
| Tropical and non-tropical sprue and forms of malabsorption associated with those diseases |
|
| Type II nephritis |
|
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
224 | (1) Thiambutosine Tablets, B.P..... | Leprosy |
| (2) Thiambutosine Injection |
|
225 | Thiamine Hydrochloride Tablets, B.P. | Any disease or condition in a pensioner |
226 | Thiethylperazine Tablets and Suppositories | Radiation sickness |
| Nausea resulting from cytotoxic therapy | |
227 | (1) Thioridazine Tablets, B.P....... | Any disease or condition in a pensioner |
| (2) Thioridazine | The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with either or both of the following pharmaceutical benefits— |
|
| Thioridazine |
|
| Thioridazine Tablets, B.P. |
|
| With the written authority of the Director-General— |
|
| Hereditary chorea (Huntington’s) |
|
| Malignant neoplasia (late stage) |
|
| Radiation sickness |
|
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
228 | Thyrotrophin................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Fifth Schedule—continued
First Column | Second Column | Third Column |
Item No. | Pharmaceutical Benefit | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
229 | Tragacanth, Indian (Gum Karaya) | Ileostomy or colostomy conditions |
230 | .......................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
231 | Tretamine................... | Treatment in malignant neoplasia |
232 | Triacetyloleandomycin........... | Amoebiasis |
|
| Brucellosis |
|
| Leptospirosis |
|
| Lymphogranuloma venereum |
|
| Pneumonia due to mycoplasma pneumoniae |
|
| Pneumonia, staphylococcal |
|
| Psittacosis |
|
| Rickettsioses |
|
| Staphylococcal septicaemia |
|
| Actinomycosis, Trachoma, or any bacterial or spirochaetal infections where these cannot be safely and effectively treated by sulphonamides, phenoxymethylpenicillin or phenethicillin |
233 | (1) Trifluoperazine Tablets, B.P..... | Any disease or condition in a pensioner |
| (2) Trifluoperazine Hydrochloride, B.P. | The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Trifluoperazine Hydrochloride, B.P. or Trifluoperazine Tablets, B.P. |
|
| With the written authority of the Director-General— |
|
| Hereditary chorea (Huntington’s) |
|
| Malignant neoplasia (late stage) |
|
| Radiation sickness |
|
| The treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
234 | Triglyde.................... | With the written authority of the Director-General, proven malabsorption |
235 | Trimetaphan Injection, B.P........ | Hypotensive in anaesthesia |
236 | Trimethoprim with Sulphamethoxazole | Any disease or condition in a patient receiving treatment in or at an approved hospital |
237 | Vadrine..................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
238 | Velactin..................... | With the written authority of the Director-General— |
|
| Galactosaemia |
|
| Homocystinuria |
|
| Lactose intolerance |
|
| Milk allergy in children under the age of four years |
239 | (1) Vinblastine Sulphate.......... | Treatment in malignant neoplasia |
| (2) Vincristine Sulphate |
|
240 | Vinyl Pyrrolidone and Vinyl Acetate with Benzocaine Aerosol Spray | Ileostomy or colostomy conditions |
241 | (1) Viomycin Sulphate........... | Tuberculosis |
| (2) Viomycin Sulphate Injection, B.P. |
|
242 | Vitamin A with Thiamine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D Tablets and Capsules | Any disease or condition in a pensioner |
THE SCHEDULES
FIRST SCHEDULE Regulation 2.
Amendments of the First Schedule to the National Health (Pharmaceutical Benefits) Regulations
1. After item 4 insert—
“ 4a. Alcohol (95%) ”.
2. After item 6 insert—
“ 6a. Amethocaine Hydrochloride ”.
3. After item 16 insert—
“ 16a. Arachis Oil ”.
4. After item 23 insert—
“ 23a. Bendrofluazide ”.
5. After item 37 insert—
“ 37a. Camphor ”.
6. After item 52 insert—
“ 52a. Chloroform ”.
7. After item 73 insert—
“ 73a. Concentrated Peppermint Water ”.
8. After item 76 insert—
“ 76a. Cottonseed Oil ”.
9. After item 103 insert—
“ 103a. Dextrose
103b. Dextrose Monohydrate ”.
10. After item 115 insert—
“ 115a. Dilute Alcohols ”.
11. After item 135 insert—
“ 135a. Ether Anaesthetic ”.
12. After item 143 insert—
“ 143a. Eucalyptus Oil ”.
13. After item 187 insert—
“ 187aa. Industrial Methylated Spirit ”.
14. After item 199 insert—
“ 199a. Laevulose ”.
15. After item 210 insert—
“ 210a. Maize Oil ”.
16. After item 222 insert—
“ 222a. Mepyramine Maleate
222b. Mepyramine Tablets ”.
17. After item 240 insert—
“ 240a. Methylprednisolone Tablets ”.
18. After item 273 insert—
“ 273a. Olive Oil ”.
19. After item 291 insert—
“ 291a. Peppermint Oil ”.
20. Omit item 321.
21. Omit item 356.
22. Omit items 386 to 388 (inclusive), insert—
“ 386. Sulphadimethoxine
386a. Sulphadimidine Injection
387. Sulphadimidine Sodium
388. Sulphamethizole ”.
23. After item 427 insert—
“ 427a. Turpentine Oi l”.
_________
SECOND SCHEDULE Regulation 3.
Amendments of the Second Schedule to the National Health (Pharmaceutical
Benefits) Regulations
1. Omit from item 8 “ Amino Acids with Sorbitol and Ethanol ” (in the third column), insert—
“ Amino Acids with Sorbitol and Alcohol ”.
2. Omit item 30.
3. After item 63 insert—
“ 63a | Dihydrocodeine Acid Tartrate..... | — ”. |
4. Omit item 97.
5. Omit item 104.
6. Omit item 117.
7. After item 149 insert—
“ 149a | Pentobarbitone............... | Barbitone Sodium |
|
| Phenobarbitone Sodium |
|
| Pentobarbitone ”. |
8. After item 174 insert—
“ 174a | Sodium Acid Citrate............ | — ”. |
9. After item 177 insert—
“ 177a | Sorbitol.................... | Amino Acids with Sorbitol |
|
| Amino Acids with Sorbitol and Alcohol ”. |
10. Insert in item 186 “ Trimethoprim with Sulphamethoxazole ” (in third column).
11. Omit from item 184 “ Streptomycin Sulphate with Sulphaguanidine B.P.C.” (in the third column).
12. After item 201 insert—
“ 201a | Tiemonium Iodide............. | — ”. |
13. After item 207 insert—
“ 207a | Trimethoprim................ | Trimethoprim with Sulphamethoxazole ”. |
14. Omit item 209, insert—
“ 209 | Vinyl Acetate................ | Vinyl Pyrrolidone and |
|
| Vinyl Acetate with Benzocaine |
209a | Vinyl Pyrrolidone............. | Vinyl Acetate and |
|
| Vinyl Pyrrolidone with Benzocaine ”. |
15. Omit item 213.
———
THIRD SCHEDULE Regulation 4.
Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations
1. After item 25 insert—
“ 25a. Ambenonium Chloride ”.
2. Omit item 48.
3. Omit item 56.
4. Omit item 79.
5. Omit item 89.
6. Omit item 93.
7. Omit item 115.
8. After item 127 insert—
“ 127a. Dihydrocodeine Acid Tartrate ”.
9. Omit item 135.
10. After item 138a insert—
“ 138b. Droperidol ”.
11. Omit item 155.
12. After item 173 insert—
“ 173a. Glibenclamide ”.
13. Omit item 187.
14. After item 196a. insert—
“ 196b. Injection of Amino Acids with Sorbitol and Alcohol
196c. Injection of Casein Hydrolysate with Laevulose and Alcohol
196d. Injection of Casein Hydrolysate and Dextrose
196e. Injection of Dextran with Dextrose
196f. Injection of Potassium Chloride with Sodium Lactate and Dextrose
196g. Injection of Sodium Chloride with Potassium Chloride, Calcium Chloride and Dextrose
196h. Injection of Sodium Chloride with Sodium Lactate and Dextrose ”.
15. Omit item 207
16. After item 223 insert—
“ 223a. Maphenide Acetate ”.
17. Omit item 235.
18. After item 266 insert—
“ 266a. Oxprenolol ”.
19. After item 285 insert—
“ 285a. Pentazocine Lactate ”.
20. After item 286 insert—
“ 286a. Pentobarbitone
286b. Peritoneal Dialysis Solution with Dextrose ”.
21. After item 328 insert—
“ 328a. Rauwolfia Serpentina, B.P.C.”.
22. After item 345 insert—
“ 345a. Sodium Lactate Compound Injection B.P. with Dextrose ”.
23. Omit item 350.
24. After item 384 insert—
“ 384a. Thiabendazole ”.
25. Omit item 405, insert—
“ 405. Trimethoprim ”.
26. Omit item 414.
27. After item 417 insert—
“ 417a. Vinyl Acetate
417b. Vinyl Pyrrolidone ”.
28. Omit item 419a.
Printed by Authority by the Government Printer of the Commonwealth of Australia